1. Home
  2. RAPT vs UTSI Comparison

RAPT vs UTSI Comparison

Compare RAPT & UTSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RAPT
  • UTSI
  • Stock Information
  • Founded
  • RAPT 2015
  • UTSI 1991
  • Country
  • RAPT United States
  • UTSI China
  • Employees
  • RAPT N/A
  • UTSI N/A
  • Industry
  • RAPT Biotechnology: Pharmaceutical Preparations
  • UTSI Telecommunications Equipment
  • Sector
  • RAPT Health Care
  • UTSI Telecommunications
  • Exchange
  • RAPT Nasdaq
  • UTSI Nasdaq
  • Market Cap
  • RAPT 30.8M
  • UTSI 25.4M
  • IPO Year
  • RAPT 2019
  • UTSI 2000
  • Fundamental
  • Price
  • RAPT $0.89
  • UTSI $2.45
  • Analyst Decision
  • RAPT Hold
  • UTSI
  • Analyst Count
  • RAPT 10
  • UTSI 0
  • Target Price
  • RAPT $5.00
  • UTSI N/A
  • AVG Volume (30 Days)
  • RAPT 386.3K
  • UTSI 8.3K
  • Earning Date
  • RAPT 11-12-2024
  • UTSI 09-05-2024
  • Dividend Yield
  • RAPT N/A
  • UTSI N/A
  • EPS Growth
  • RAPT N/A
  • UTSI N/A
  • EPS
  • RAPT N/A
  • UTSI N/A
  • Revenue
  • RAPT N/A
  • UTSI $14,958,000.00
  • Revenue This Year
  • RAPT N/A
  • UTSI N/A
  • Revenue Next Year
  • RAPT N/A
  • UTSI N/A
  • P/E Ratio
  • RAPT N/A
  • UTSI N/A
  • Revenue Growth
  • RAPT N/A
  • UTSI 14.41
  • 52 Week Low
  • RAPT $0.82
  • UTSI $2.20
  • 52 Week High
  • RAPT $27.35
  • UTSI $3.54
  • Technical
  • Relative Strength Index (RSI)
  • RAPT 36.23
  • UTSI 36.82
  • Support Level
  • RAPT $0.84
  • UTSI $2.57
  • Resistance Level
  • RAPT $1.18
  • UTSI $2.80
  • Average True Range (ATR)
  • RAPT 0.10
  • UTSI 0.15
  • MACD
  • RAPT 0.01
  • UTSI -0.03
  • Stochastic Oscillator
  • RAPT 17.00
  • UTSI 0.00

About RAPT RAPT Therapeutics Inc.

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

About UTSI UTStarcom Holdings Corp.

UTStarcom Holdings Corp operates as a telecom infrastructure provider. It develops technology for bandwidth from cloud-based services, mobile, streaming, and other applications. The range of solutions is designed to expand and modernize telecommunications networks through smooth network system integration, lower operating costs, and increased broadband access. The business activity of the firm is operated through the Equipment and Service segment. The Equipment segment is focused on equipment sales, including network infrastructure and application products, and the Service segment is engaged in providing services and support of equipment products and also the new operational support. The company operates in China, India, Japan, Taiwan and other countries.

Share on Social Networks: